3Z Pharmaceuticals

Executive Summary

3Z Pharmaceuticals is a European biotech company leveraging a unique zebrafish screening platform to discover and repurpose approved small molecules for CNS disorders. Founded in 2015 and headquartered in Reykjavik, the company combines advanced disease modeling with behavioral genetics to identify novel indications for existing drugs, aiming to accelerate development timelines and reduce risk. While the company remains private with limited public disclosures, its strategy targets high-unmet-need areas such as neurodevelopmental and neurodegenerative conditions. The platform's potential for cost-effective drug discovery positions it as an attractive partner for larger pharmaceutical companies. Near-term catalysts include progress toward clinical validation of lead candidates, which could drive valuation increases and strategic collaborations.

Upcoming Catalysts (preview)

• Q4 2026Lead candidate IND filing or Phase 1 initiation40% success
• Q2 2027Strategic partnership with major pharma for CNS repurposing programs35% success
• Q3 2026Publication of preclinical efficacy data in peer-reviewed journal70% success